| 1 | TITLE (120 CHARACTERS MAX): |
|----|--|
| 2 | Investigating the relationship between IGF-I, -II and IGFBP-3 concentrations and later-life cognition |
| 3 | and brain volume |
| 4 | SHORT TITLE (50 CHARACTERS MAX): IIS, cognition and brain volume in the NSHD |
| 5 | AUTHORS: |
| 6 | Antoine Salzmann ¹ , Sarah-Naomi James ¹ , Dylan M. Williams ^{1,2} , Marcus Richards ¹ , Dorina Cadar ³ , |
| 7 | Jonathan M. Schott ⁴ , William Coath ⁴ , Carole H. Sudre ^{4,5} , Nishi Chaturvedi ¹ and Victoria Garfield ¹ |
| 8 | INSTITUTIONS: |
| 9 | ¹ MRC Unit for Lifelong Health and Ageing at UCL, University College London, London, UK |
| 10 | ² Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. |
| 11 | ³ Department of Behavioural Science and Health, University College London, London, UK |
| 12 | ⁴ Department of Neurodegenerative Disease, The Dementia Research Centre, UCL Queen Square |
| 13 | Institute of Neurology, London, UK |
| 14 | ⁵ School of Biomedical Engineering and Imaging Sciences, King's College London, London, UK |
| 15 | CORRESPONDING AUTHOR: |
| 16 | Antoine Salzmann |
| 17 | MRC Unit for Lifelong Health and Ageing at UCL |
| 18 | University College London |
| 19 | 5 th floor 1-19 Torrington Place London WC1E 7HB London, United Kingdom |
| 20 | Phone: +44 (0) 2076705723 |

21 Email: antoine.salzmann.14@ucl.ac.uk

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

FUNDING: This work was supported by the UK Medical Research Council, which provides core funding for the MRC Unit For Lifelong Health and Ageing at UCL and the MRC National Survey of Health and Development (MC UU 00019/1) and supports AS, NC, DW, MR, SNJ (MC ST LHA 2019; MC UU 0019/2, MC UU 0019/3). Insight 46 is principally funded by grants from Alzheimer's Research UK (and SNJ ARUK-PG2014-1946, ARUK-PG2017-1946), the Medical Research Council Dementias Platform UK (CSUB19166), the Wolfson Foundation (PR/ylr/18575) and The Drake Foundation. JMS acknowledges the EPSRC (EP/J020990/1) and European Union's Horizon 2020 research and innovation programme (Grant 666992) and a Weston Brain Institute and Selfridges Group Foundation award (176724). DC is funded by the National Institute on Aging (RO1AG017644) and ESRC (ES/S013830/1). CHS is supported by an Alzheimer's Society Junior Fellowship (AS-JF-17-011). VG is funded by Joint Diabetes UK and British Heart Foundation (15/0005250). DISCLOSURE: JMS has received research funding from Avid Radiopharmaceuticals (a wholly-owned subsidiary of Eli Lilly), has consulted for Roche Pharmaceuticals, Biogen, and Eli Lilly, given educational lectures sponsored by GE, Eli Lilly and Biogen, and serves on a Data Safety Monitoring Committee for Axon Neuroscience SE. NC receives funds for serving on a Data Safety Monitoring Committee for a study sponsored by AstraZeneca. All other authors have no conflicts of interest to declare.

KEYWORDS (6 max): IGF-I, IGF-II, Cognition, Ageing, Epidemiology, Brain volume

Abstract (250 words max) Background: The insulin/insulin-like signalling (IIS) pathways, including Insulin-like Growth Factors (IGFs), varies with age. However, their association with late-life cognition and neuroimaging parameters is not well characterised. Methods: Using data from the British 1946 birth cohort we investigated associations of IGF-I, -II and IGFBP-3 (measured at 53 and 60-64 years) with cognitive performance (word learning test (WLT) and visual letter search (VLS) – at 60-64y and 69y) and cognitive state (Addenbrooke's Cognitive Exam-III (ACE-III) - at 69-71y), and in a proportion, quantified neuroimaging measures (whole brain volume (WBV); white matter hyperintensity volume (WMHV); hippocampal volume (HV)). Regression models included adjustments for demographic, lifestyle and health factors. Results: Higher IGF-I and IGF-II at 53y was associated with higher ACE-III scores (\$0.07 95%CI [0.02,0.12]; score_{ACF-III} 89.48 [88.86,90.1], respectively). IGF-II at age 53y was additionally associated with higher WLT scores (score_{WLT} 20 [19.35,20.65]). IGFBP-3 at 60-64y was associated with favourable VLS score at 60-64y and 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.02,0.12], respectively), higher memory and cognitive state at 69y (ß 0.07 [0.01,0.12]; ß 0.07 [0.01,0.13], respectively) and reduced WMHV (ß -0.1, [-0.21,-0.00]). IGF-I/IGFBP-3 at 60-64y was associated with lower VLS scores at 69y (ß -0.08, [-0.15,-0.02]). Conclusions: Increased measure in IIS parameters (IGF-I, -II and IGFBP-3) relate to better cognitive state in later life. There were apparent associations with specific cognitive domains (IGF-II relating to memory; IGFBP-3 to memory, processing speed and WMHV; and IGF-I/IGFBP-3 molar ratio with slower processing speed). IGFs and IGFBP-3 are associated with favourable cognitive function outcomes.

Word count: 250 words

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

Introduction

The Growth Hormone/Insulin-like Growth Factor signalling pathway is thought to play a key role in ageing health and the determination of age-related diseases. In humans, this pathway is regulated through the somatotropic axis, which consists mainly of growth hormone (GH), Insulin-like Growth Factors (IGF) and their respective binding proteins ¹. IGF-I binds to IGF binding proteins (IGFBP) in high-affinity complexes to prevent degradation and binding to the IGF-I receptor (IGF1R), thus leaving concentrations of 'free' circulating IGF-I relatively low. As such, the ratio of IGF-I to binding proteins provides an indication of bioavailability ¹⁻³, whilst also mediating its effect via IGF1R; IGF-II bioavailability is also regulated by the IGF2 receptor ⁴. IGFBP-3, however, has also been shown to have IGF-independent associations on phenotypes ⁵.

Whereas research supports an important role of Insulin/Insulin Growth Factor-like Signalling (IIS) in early brain development and neuroplasticity, as evidenced by developmental defects associated with mutations in the IGF1R gene, its role in the maintenance of brain function is less well understood ^{6,7}. Observational studies are conflicting, with some reporting protective, detrimental, 'U' shape and null associations ^{8,9}. The relationship between IGF-II and cognition and neurological health, on the other hand, remains largely uncharacterised, with only one study to date, which reported raised IGF-II concentrations in association with better cognition, while no association of IGF-I was observed ¹⁰

The MRC National Survey for Health and Development (NSHD; also known as the 1946 British Birth Cohort), provides an ideal opportunity to study the relationship between measures of the IIS axis through mid-life, and cognition and brain volume in later life ¹¹. IGF-I and -II collection at multiple time points may help resolve previous discrepant findings by considering differential associations of age, and duration of follow-up. Additionally the NSHD has a wealth of data across the life-course, allowing us to control for potential confounders which have been omitted or based on

recalled data in past studies, such as early-life cognition and affective symptoms. Finally, neuroimaging data enables associations with brain volume and neurovascular health to be studied in tandem with cognitive function.

We aimed to examine the independent associations of IGF-I, IGFBP-3, and IGF-II measured at ages 53 and 60-64 with cognitive function at ages 60-64 and 69, and volumetric and cerebrovascular neuroimaging parameters (total brain, hippocampal and white matter hyperintensity volumes) at age 69-71.

Methods

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

Study participants

The NSHD recruited 5,362 participants born within one week in March 1946 in England, Scotland and Wales. The cohort has remained in continuous follow-up from birth to date, with 24 sweeps of investigation ¹². Cognitive function at age 69 was our primary outcome. At this age, 2149 participants were interviewed. The loss to follow-up was due to death (19.1%), refusal (20.6%), emigration or being temporarily abroad (10.8%) or because the participant could not be contacted or traced (7.8%). Figure 1 outlines the number of participants with information concerning exposure and outcome variables and the final sample (n=1762) used for analysis.

We additionally examined associations with neuroimaging outcomes in a sub-sample who had participated in the neuroimaging sub-study, Insight 46 ¹³. Details have previously been published ¹³, but in brief this study included 502 individuals who underwent positron emission tomography magnetic resonance imaging (PET-MRI) scanning using a single Biograph mMR 3T PET-MRI scanner (Siemens Healthcare, Erlangen), with simultaneous acquisition of PET/MRI data, including volumetric (1.1 mm isotropic) T1 and fluid-attenuated inversion recovery (FLAIR) sequences ¹³. Volumetric T1weighted and FLAIR images underwent visual quality control prior to processing following an automated pipeline ¹³. Relevant imaging measures were isolated as follows: total brain volume (TBV) using Multi-Atlas Propagation and Segmentation ¹⁴, mean hippocampal volume (HV) using Similarity and Truth Estimation for Propagated Segmentations ¹⁵, total intracranial volume (TIV) using SPM12 (Wellcome Centre for Human Neuroimaging) and white matter hyperintensity volume (WMHV) using Bayesian model selection (BaMoS) 16,17. WMHV was isolated from 3D T1 and FLAIR images followed by visual inspection to generate a global WMHV, including subcortical grey matter but excluding infratentorial regions ^{17,18}. Eligibility criteria, the study protocol, and a comparison of those who did and who did not participate in Insight 46 have been described in detail elsewhere ^{13,18}. Of the 502 Insight 46 participants, complete neuroimaging and ACE-III data were available for 378.

Measures

IGF-I, IGF-II and IGFBP-3 concentrations

Blood samples were collected at age 53 (non-fasting), and age 60-64 (fasting). Samples were stored at -80°C and assayed together. IGF-I, IGF-II and IGFBP-3 concentrations were obtained by radioimmunoassay using standard protocols in the same laboratory, as previously described ¹⁹. The intra-assay coefficient of variation (CV) for IGF-I, IGF-II and IGFBP-3 were 3.4%, 2.8% and 3.9%, respectively. The inter-assay CV was 13.7%, 7.4% and 11.7% for IGF-I, IGF-II and IGFBP-3, respectively ²⁰. IGF-I, IGF-II and IGFBP-3 values were converted from ng/ml to standard SI units: nmol/L ²¹. IGF-I/IGFBP-3 values were calculated as molar ratios as an indicator of IGF-I bioavailability. Repeat measures were available for between 1117 and 1127 participants, for IGF-I/IGFBP-3 ratio and IGFBP-3, respectively.

Cognitive performance measures

Three separate tests were used to measure cognitive domains. At 60-64 and 69, standardised versions of a Word Learning Test (WLT) and Visual Letter Search test (VLS) were used to assess memory and processing speed, respectively. The WLT consists of a 15-word learning task devised for the NSHD. Each word was shown to the participant for 2 seconds and partcipants were asked to immediately write down as many words as they could remember. The task was repeated three times, and the scores were summed (max = 45), which is representative of short-term episodic memory ^{22,23}. The VLS required participants to scan for the letters 'P' and 'W' among other letters and cross out as many of them within one minute. Search speed score was based on how far the participant got in the grid search, with a maximum score of 600 signifying they had completed the whole grid ²².

The Addenbrooke's Cognitive Examination-III (ACE-III) is a test for cognitive state administered at age 69 ^{24,25}. The test assesses five domains, each with different score ranges:

Attention (0-18), Memory (0-26), Fluency (0-14), Language (0-26) and Visuospatial (0-16). The test was administered either online using an iPad (http://www.acemobile.org/) or by paper if the former was not possible. Paper tests were scored by trained personnel ^{24,26}. Unlike most tests of cognitive state, the ACE-III total score (max = 100) has a quasi-normal distribution, making it appropriate for parametric statistical analyses.

Covariates

Covariates were selected *a priori*, based on previous studies and added into our models successively. Model 1 had sex, Model 2 included additional adjustments for childhood cognition and educational attainment, Model 3 added smoking status at the time of exposure and Model 4 added affective symptoms at the time of outcome ^{10,27,28}. The same models were used when investigating the relationship between exposures and brain volume with TIV additionally controlled for in all volumetric outcome models.

Childhood cognition at age 8 was assessed by four tests administered by trained observers: reading comprehension, word pronunciation, vocabulary and non-verbal reasoning. Total scores were standardised to the study population. Lifetime education attainment was based on the highest educational qualification by the age of 43 years ²⁶ and categorised as 1) no qualification or vocational qualifications 2) ordinary, advanced secondary and 3) tertiary qualifications. Smoking status was obtained from questionnaires and classified into current smoker, ex-smoker and never smoker at age 53 and 60-64 ²⁹. Affective symptoms were self-reported at ages 60-64 and 69 years using the 28-item General Health Questionnaire (GHQ-28) ³⁰. A threshold, set at the recommended 4 (non-case) / 5 (case) cut was imposed on the GHQ-28 total score to determine case-level symptoms ^{30,31}.

Statistical analyses

WMHV was log_e-transformed to account for skewness. ANOVA tests were used to examine exposure and outcome variable differences at different timepoints. Within the selected sample,

missing data ranged from 0.1% to 27.9% for affective case symptoms (age 69) and IGF-I/IGFBP-3 molar ratio (age 60-64) respectively. To account for attrition at follow-up, missing data for exposure, WLT, VLS and covariate variables were imputed using multiple imputation by chained equations (MICE). Imputation models included all model variables, except for volumetric outcomes. Datasets were imputed 20 times using a Bayesian linear regression model ³².

Linear regression models were used to assess the relationship between exposure and outcomes. Results are presented as standardised beta values with 95% confidence intervals. To determine whether the associations of IGFs and IGFBP-3 with cognition and brain volume differed by sex, which may warrant stratification, an interaction term for sex was tested at the 10% significance level for all exposures. No interaction was found between sex and exposure variables, so main models were not stratified by sex. In addition, a quadratic term for the exposure was tested to explore the possibility of non-linear associations. A quadratic relationship was observed between IGF-II and general cognitive state and visual memory. Therefore, for associations with cognitive state, IGF-II measurements were categorised into tertiles.

All statistical analyses were performed in R version 3.5.2 ³³. Multiple imputation was performed using the 'mice' package in R³². Relevant R script is available upon request.

Results

Sample characteristics

Of the 1762 NSHD participants with cognitive state measured at age 69, 849 (48%) were male, and 913 (52%) were female. The Insight 46 imaging sub-study at age 69-71 (mean age: 70.67 years, SD: 0.67) included 378 of these 1762 NSHD participants. Of these, 194 (51%) were male and 184 (49%) female (Table 1). Whilst those who attended the clinic at ages 53 and 60-64 were overall healthier – less likely to smoke, higher Socioeconomic status (SES) and were more educated – , the

concentration of IGF-pathway components was similar between participants in the full sample and those included in the final analysis (data not shown).

In the entire cohort at age 60-64, the overall pattern shows that IGF-I concentrations were lower, and IGFBP3 levels substantially lower than at age 53 (Table 1). As a result, IGF-I/IGFBP3 ratio was higher at age 60-64 than 53. IGF-II concentrations were lower at age 60-64 than age 53. Visual memory (WLT) and processing speed (VLS) were lower with increasing age at investigation, as previously described (Table 1) ³⁴.

IGF-I

Higher IGF-I concentrations at age 53 and 60-64 were associated with better cognitive function for the WLT and ACE-III cognitive measures, but not for the VLS (Figure 2). These associations reached conventional levels of statistical significance for IGF-I at age 53 and ACE-III at age 69 (β 0.07, 95% CI 0.02,0.12, p = 0.008). Adjustment for childhood cognition and educational attainment attenuated this estimate to β 0.04, 95% CI 0.00,0.09, p = 0.063. Further adjustment for smoking status and emotional symptoms did not alter the estimate (Figure 2). Excluding participants with case-level affective symptoms at baseline had no qualitative impact on the magnitude or direction of associations (data not shown).

In the subjects with imaging available, higher concentrations of IGF-I at age 60-64 were directionally associated with a 8% lower WMHV at age 71 years (95% CI -19%, 3%, p = 0.142), yet did not reach conventional levels of significance. Adjustment for the covariates did not affect this trend (Figure 3).

IGF-I/IGFBP-3 ratio

IGF-I/IGFBP-3 ratio was associated with lower VLS and ACE-III scores (Figure 2). Elevated IGF-I/IGFBP-3 concentrations at age 60-64 were associated with lower VLS score at age 69 (β -0.08, 95% CI -0.15,-0.02, p = 0.019) (Figure 2). In contrast to IGF-I models, adjustment for childhood cognition

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

and education did not attenuate effect sizes. No clear associations with brain volume were observed (Figure 3). IGFBP-3 Higher concentrations of IGFBP-3 at age 60-64 were associated with faster processing speed at age 60-64 and 69 (% 0.07, 95% CI 0.01,0.12, p = 0.014 and % 0.07, 95% CI 0.02,0.12, p = 0.012, respectively) (Figure 2). The addition of covariates did not affect this association (Figure 2). Higher concentrations of IGFBP-3 at age 60-64 were additionally associated with higher scores for memory and cognitive state at age 69 (% 0.07, 95% CI 0.01,0.12, p = 0.017 and % 0.07, 95% CI 0.01,0.13, p = 0.033, respectively) (Figure 2). Adjustment for education and childhood cognition attenuated these estimates to & 0.05, 95% CI 0:00,0.10, p = 0.034 and & 0.05, 95% CI 0:00,0.10, p = 0.07, respectively (Figure 2). Higher concentrations of IGFBP-3 at age 60-64 were additionally associated with a 10% lower WMHV at age 71 years (β -0.1, 95% CI -0.21,0.00, p = 0.059) (Figure 3). Adjustment for the covariates did not affect this association (Figure 3). IGF-II Similarly to IGF-I, higher concentrations of IGF-II were associated with better cognitive function for the WLT and ACE-III cognitive measures, but not with VLS (Figure 4). At age 53, the lowest tertile of circulating IGF-II concentration was associated with a lower ACE-III score at age 69 (score_{ACE-III} 89.48, 95% CI 88.86,90.1, p = 0.022, tertile 1) (Figure 4). Similarly, the lowest tertile of IGF-II at age 53 were associated with lower memory at age 69 (score_{WLT} 20, 95% CI 19.35, 20.65, p = 0.085, tertile 1). As for IGF-I/IGFBP-3 ratio, no associations with brain volume were observed (Figure 3). Discussion In this UK population sample, IGF-I and -II concentrations at age 53, and IGF-I concentrations at age 60-64, were positively associated with cognitive state at age 69, assessed by

oncentrations at age 60-64, were positively associated with cognitive state at age 69, assessed t

the Addenbrooke's Cognitive Examination (ACE-III) and verbal memory, but not with processing speed. Higher IGFBP-3 concentrations at age 60-64 were associated with overall higher cognition. Adjustment for childhood cognition and educational attainment attenuated these associations, but did not wholly account for them. In addition, IGF-I and IGFBP-3 at age 60-64 were associated with lower white matter hyperintensity burden at age 69-71. Multivariable adjustment did not notably alter these associations. Surprisingly, there was a trend towards worse cognitive state and processing speed in those with higher IGF-I/IGFBP-3 ratio levels.

The positive relationship between IGF-I and general cognitive state reflects findings in the Nurses Health Cohort (NHC), which found an association between IGF-I and verbal memory attenuated after adjustment for educational attainment ³⁵. NHC participants were of similar age to NSHD participants at our 2nd baseline (60-64) years, and the main follow-up point (69 years). Additionally, though, we suggest associations are similar in men and women, and show that cognitive state is related to IGF-I sampled earlier in life, at age 53. Our findings conflict with observation of a an adverse ³⁶, or 'U' shaped relation ³⁷, of IGF-I on cognition. The former analyses were performed cross-sectionally in much older participants (≥95 years), while the latter spanned ages 48-88 at follow-up. Age-dependent pleiotropic effects of IGF-I could potentially account these conflicting findings; specifically, if IGF-I acts beneficially in middle age and early older age, but has adverse effects in late older age. A 'U' shaped association may therefore be observed if participants span early and late older age.

The IGF pathway plays an essential role in brain development and homeostasis, including neurogenesis, neuronal differentiation and angiogenesis ^{8,38}. Thus, the apparent beneficial association of increased pathway activation with cognitive and brain outcomes may be driven by a combination of developmental – with better cerebral development during foetal and early life and neuroprotective pathways – with increased neurogenesis and improved outcomes following cerebrovascular events ^{8,39–41}. Prospective analyses of the Framingham Heart Study found that higher

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

concentrations of IGF-I were associated with larger brain volumes in healthy participants, potentially suggestive of some protection against neurodegeneration ⁴². Association magnitudes were doubled in the parent versus the offspring cohort (mean ages 79 years and 61 years, respectively), highlighting an important age dependency. Whilst we did not observe an association between IGF-I and TBV, IGF-I was associated with lower WMHV, an indicator of cerebral small vessel damage. To our knowledge, no previous study has explored the association between IGF-I and cerebral small vessel disease. A 10-year prospective study found stroke incidence to be associated with lower circulating IGF-I concentrations ⁴³. Other studies have shown improved outcomes following ischemic stroke in participants with higher IGF-I concentrations (41). In hypertensive mice, liver-specific IGF-Iknockdown treatment was associated with increased and earlier incidence of cerebral microhaemorrhages compared to control mice, likely due to impaired remodelling processes 45. Mechanisms underlying protective effects of IGF-I on the vasculature include anti-inflammatory properties, preservation of endothelial function, and a positive association with cardiovascular risk factors such as obesity and insulin resistance 43. Whilst our findings did not reach conventional levels of statistical significance, effect sizes, consistency with previous research, and strong biological plausibility supports further investigation.

Surprisingly, however, associations with the IGF-I/IGFBP-3 ratio were opposite to those observed for IGF-I alone, with the ratio associated with reduced processing speed and, to a lesser degree, cognitive state. This can be explained by IGFBP- 3 being positively associated with cognition independently of IGF-I. IGFBPs have been shown to execute IGF-I independent actions, including mediation of cell proliferation, apoptosis and survival 46,47. Furthermore, the age-related decline in IGFBP-3 concentration was markedly greater than that for IGF-I resulting in an increase in IGF-I/IGFBP-3 ratio between the two timepoints. Thus, the apparent negative association with cognitive outcomes may be the product of the differential declines in the ratio components rather than a biologically relevant association of the ratio with the cognitive outcomes.

We observed globally improved cognitive outcomes associated with increased circulating IGFBP-3 concentrations. In line with our results, higher concentrations of IGFBP-3 were found to be cross-sectionally associated with better cognitive state in women in the Mayo Clinic Study of Ageing and reduced dementia incidence in men ^{48,49}. In mice, null mutations in the *Igfbp3* gene resulted in impaired neuronal structure and signalling and spatial working memory ⁵⁰. However, findings are not consistent across studies with higher concentrations of IGFBP-3 related to poorer cognition in males in the Caerphilly Prospective Study (CaPS) ¹⁰. Our findings highlight the importance of exploring associations with individual factors that form a biologically meaningful molecular ratios, and understanding age-related changes in exposures, which, as we show, may not be equivalent across associated measures.

In addition to favourable cognitive outcomes, IGFBP-3 was conjointly associated with a 10% reduction in WMHV in our study. Several studies have implied the possibility of a beneficial association between IGFBP-3 and cerebral small vessel disease. High concentrations of circulating IGFBP-3 are associated with reduced risk of ischaemic stoke and improved functional outcomes following stroke events ^{44,51,52}. In mice, IGFBP-3 was shown to protect retinal vasculature from hyperoxia-induced vessel regression and, *in vitro*, promoted differentiation of endothelial precursor cells to endothelial cells, indicating a potential pathway by which IGFBP-3 may reduce WMHV ^{5,53}.

Few studies have examined the relationship between IGF-II and cognitive outcomes. IGF-II has traditionally been seen as relatively unimportant beyond fetal development. However, there is increasing evidence relating detrimental IGF-II expression to disease after birth ^{4,54}. To our knowledge, only one other study has investigated the role of IGF-II on later-life cognition. The CaPS found a reduced occurrence of cognitive impairment without dementia with higher circulating IGF-II concentrations, but not with cognitive state. In addition, they did not find an association between IGF-II and cognitive function ¹⁰. In our study, we found a time-dependent association between higher IGF-II at age 53 and better visual memory and cognitive state at age 69, presenting similarities to the

results obtained from the IGF-I models. This suggests a common pathway, likely via signalling downstream of the IGF-1R. Discrepancies between our findings and those from the CaPS may be driven by choice of outcome. The CaPS studied CIND, dementia and 'normal' cognitive ageing separately, therefore excluding participants with CIND or dementia from models studying 'normal' cognitive ageing. It is possible that 'normal' and 'abnormal' cognitive ageing are driven by separate mechanisms and IGF-I and IGF-II might be protective in the context of 'abnormal' cognitive ageing only.

Our study has some important strengths, including a prospective design with extended follow-up (16 years) and important confounders, including childhood cognition. To our knowledge, it is the only study to use repeat exposure and outcome measures to better understand the temporal relationship between IGFs and cognition. Age-dependent relationships may reflect separate underlying biological pathways acting at different points in the life course. In addition, it is the first study to investigate both cognitive function and structural brain measures. However, it is important to consider some limitations of the present study. Whilst associations were robust to adjustments, the observational methods used here cannot discount the possibility of residual confounding. For instance, this study did not adjust for chronic diseases which may impact IGF serum levels and associate with brain health independently of the IGF pathway.

To investigate active IGF-I, this study used the ratio of IGF-I to IGFBP-3. However, we acknowledge this to be an imprecise measure of IGF-I activity, as other binding proteins and pathway components are involved in regulating pathway activation. Furthermore, binding proteins have been shown to have IGF-I independent actions ⁴⁶. Conflicting results between IGF-I and IGF-I/IGFBP-3 in our study were seemingly explained by IGF-I-independent associations between IGFBP-3 and cognition, thereby supporting future study of IGFBP-3 independently from IGF-I. However, the use of 'free' IGF-I may provide a more accurate view of the role of unbound circulating IGF-I on brain health ⁵⁶.

Blood samples from ages 53 and 60-64 were assayed together and stored at -80°C until quantification. Therefore, measures will have been stored for varying lengths of time which may affect results, particularly if the protein is prone to degradation. However, IGF-I, -II and IGFBP-3 levels have previously been shown to remain stable following 9 years of -80°C storage, which reduced the likelihood of this occurring in our study ⁵⁷. Furthermore, biomarker concentrations may be affected by the differential fasting status when blood samples were collected at ages 53 (nonfasting) and 60-64y (fasting). However, Bereket *et al* (1996) found no associations between IGF-I and IGFBP-3 concentration and short-term fasting thus limiting the risk of fasting status being an important biasing factor in our study ⁵⁸. Finally, with the latest follow-up at age 69, participants are still not old enough for severe cognitive decline to be common, which could mean limited statistical power to detect moderate to small associations.

In light of these findings, we would suggest further studies to determine the exact domains which may be affected by IGF-I, —II and IGFBP-3 concentrations. This could be done by using an array of cognitive tests that probe distinct cognitive domains. Further studies continuing to use repeat IGF and IGFBP exposures in relation to cognition measures across the life course may help provide a better understanding of the complex relationship between the two. Re-examination of the relationships in the NSHD at an older age would be essential to understand age-dependent effects and potentially address the current inconsistencies in the field. Furthermore, genetic approaches to study the association between polygenic risk scores and cognition across the age spectrum may provide an alternate method to investigate relationships across the life course.

While repeat measures in our study have highlighted the importance of time of exposure, outcome and follow-up period, further work is required to disentangle the temporal nature of the IIS-brain health relationship. Regular IGF-I, -II, IGFBP-3 and cognition measures throughout the life course would help to elucidate this. As autocrine and paracrine IGF-I concentrations vary with age, narrowing the age range at each sample collection could also prove essential ^{59,60}. The wide age

range in a number of studies may prove responsible for some of the heterogeneity currently observed in results ^{37,56,61}.

In conclusion, in this UK birth cohort, higher circulating IGF-I and -II levels were prospectively associated with a favourable cognitive state, whilst IGF-I/IGFBP-3 ratio was associated with slower processing speed. IGF-II was additionally associated with better memory performance. IGFBP-3 was independently associated with cognitive state, memory, processing speed and WMHV. The present study has not only added to our understanding of the IIS-cognition relationship, but crucially, it has elucidated the importance of using a breadth of neuroimaging, cognitive function and state to understand more holistically how IGFs and IGFBPs relate to brain health from mid to later life.

Acknowledgements

The authors are grateful for the continued support of the NSHD study members without whom this study would not have been possible. We would also like to acknowledge Dr. Andy Wong for assistance in data extraction and management, and the Insight 46 study team.

Data availability:

Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.

References 393 394 395 Milman S, Huffman DM, Barzilai N. The somatotropic axis in human aging: Framework for the 396 current state of knowledge and future research. Cell Metab. 2016;23(6):980-989. 397 doi:10.1016/j.cmet.2016.05.014 398 2. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic 399 bioactivities. Am J Physiol Endocrinol Metab. 2000;278(6):E967-976. 400 doi:10.1152/ajpendo.2000.278.6.E967 401 Juul A, Main K, Blum WF, Lindholm J, Ranke MB, Skakkebaek NE. The ratio between serum 402 levels of insulin-like growth factor (IGF)-I and the IGF binding proteins (IGFBP-1, 2 and 3) 403 decreases with age in healthy adults and is increased in acromegalic patients. Clin Endocrinol 404 (Oxf). 1994;41(1):85-93. doi:10.1111/j.1365-2265.1994.tb03788.x 405 4. Chao W, D'Amore PA. IGF2: Epigenetic regulation and role in development and disease. 406 Cytokine Growth Factor Rev. 2008;19(2):111-120. doi:10.1016/j.cytogfr.2008.01.005 407 5. Jogie-Brahim S, Feldman D, Oh Y. Unraveling Insulin-Like Growth Factor Binding Protein-3 408 Actions in Human Disease. Endocr Rev. 2009;30(5):417-437. doi:10.1210/er.2008-0028 409 6. Dyer AH, Vahdatpour C, Sanfeliu A, Tropea D. The role of Insulin-Like Growth Factor 1 (IGF-1) in 410 brain development, maturation and neuroplasticity. Neuroscience. 2016;325:89-99. 411 doi:10.1016/j.neuroscience.2016.03.056 412 Abuzzahab MJ, Schneider A, Goddard A, et al. IGF-I Receptor Mutations Resulting in 413 Intrauterine and Postnatal Growth Retardation. N Engl J Med. 2003;349(23):2211-2222. 414 doi:10.1056/NEJMoa010107 415 Frater J, Lie D, Bartlett P, McGrath JJ. Insulin-like Growth Factor 1 (IGF-1) as a marker of 416 cognitive decline in normal ageing: A review. Ageing Res Rev. 2018;42:14-27. 417 doi:10.1016/j.arr.2017.12.002 418 Gubbi S, Quipildor GF, Barzilai N, Huffman DM, Milman S. 40 YEARS of IGF1: IGF1: the Jekyll 419 and Hyde of the aging brain. J Mol Endocrinol. 2018;61(1):T171-T185. doi:10.1530/JME-18-0093 420 421 10. Green CJ, Holly JMP, Bayer A, et al. The role of IGF-I, IGF-II, and IGFBP-3 in male cognitive aging 422 and dementia risk: the Caerphilly Prospective Study. J Alzheimers Dis JAD. 2014;41(3):867-875. 423 doi:10.3233/JAD-132183 424 Kuh D, Wong A, Shah I, et al. The MRC National Survey of Health and Development reaches age 425 70: maintaining participation at older ages in a birth cohort study. Eur J Epidemiol. 426 2016;31(11):1135-1147. doi:10.1007/s10654-016-0217-8 427 Wadsworth M, Kuh D, Richards M, Hardy R. Cohort Profile: The 1946 National Birth Cohort 428 (MRC National Survey of Health and Development). Int J Epidemiol. 2006;35(1):49-54. 429 doi:10.1093/ije/dyi201

,,,,

430 Lane CA, Parker TD, Cash DM, et al. Study protocol: Insight 46 – a neuroscience sub-study of 431 the MRC National Survey of Health and Development. BMC Neurol. 2017;17(1):75. 432 doi:10.1186/s12883-017-0846-x 433 Leung KK, Barnes J, Modat M, et al. Brain MAPS: An automated, accurate and robust brain 434 extraction technique using a template library. NeuroImage. 2011;55(3):1091-1108. 435 doi:10.1016/j.neuroimage.2010.12.067 436 15. Jorge Cardoso M, Leung K, Modat M, et al. STEPS: Similarity and Truth Estimation for 437 Propagated Segmentations and its application to hippocampal segmentation and brain 438 parcelation. Med Image Anal. 2013;17(6):671-684. doi:10.1016/j.media.2013.02.006 439 Sudre CH, Cardoso MJ, Bouvy WH, Biessels GJ, Barnes J, Ourselin S. Bayesian Model Selection 440 for Pathological Neuroimaging Data Applied to White Matter Lesion Segmentation. IEEE Trans 441 Med Imaging. 2015;34(10):2079-2102. doi:10.1109/TMI.2015.2419072 442 Lane CA, Barnes J, Nicholas JM, et al. Associations Between Vascular Risk Across Adulthood and 443 Brain Pathology in Late Life: Evidence From a British Birth Cohort. JAMA Neurol. 444 2020;77(2):175-183. doi:10.1001/jamaneurol.2019.3774 445 Lane CA, Barnes J, Nicholas JM, et al. Associations between blood pressure across adulthood 446 and late-life brain structure and pathology in the neuroscience substudy of the 1946 British 447 birth cohort (Insight 46): an epidemiological study. Lancet Neurol. 2019;18(10):942-952. 448 doi:10.1016/S1474-4422(19)30228-5 449 Lemmey A, Maddison P, Breslin A, et al. Association between insulin-like growth factor status 450 and physical activity levels in rheumatoid arthritis. J Rheumatol. 2001;28(1):29-34. 451 Bann D, Holly JMP, Lashen H, et al. Changes in insulin-like growth factor-I and -II associated 452 with fat but not lean mass in early old age. Obes Silver Spring Md. 2015;23(3):692-698. 453 doi:10.1002/oby.21002 454 Kucera R, Topolcan O, Pecen L, et al. Reference values of IGF1, IGFBP3 and IGF1/IGFBP3 ratio in 455 adult population in the Czech Republic. Clin Chim Acta. 2015;444:271-277. 456 doi:10.1016/j.cca.2015.02.036 457 Richards M, Barnett JH, Xu MK, et al. Lifetime affect and midlife cognitive function: prospective 458 birth cohort study. Br J Psychiatry. 2014;204(3):194-199. doi:10.1192/bjp.bp.113.128942 459 Richards M, Shipley B, Fuhrer R, Wadsworth MEJ. Cognitive ability in childhood and cognitive 460 decline in mid-life: longitudinal birth cohort study. BMJ. 2004;328(7439):552. 461 doi:10.1136/bmj.37972.513819.EE 462 Hsieh S, Schubert S, Hoon C, Mioshi E, Hodges JR. Validation of the Addenbrooke's Cognitive 463 Examination III in frontotemporal dementia and Alzheimer's disease. *Dement Geriatr Cogn* 464 Disord. 2013;36(3-4):242-250. doi:10.1159/000351671 465 Kuh D, Hardy R, Richards M, et al. MRC NSHD 2013-2018 Data. Published online 2016. 466 doi:10.5522/NSHD/Q103 467 Richards M, James S-N, Sizer A, et al. Identifying the lifetime cognitive and socioeconomic

Open. 2019;9(4):e024404. doi:10.1136/bmjopen-2018-024404

antecedents of cognitive state: seven decades of follow-up in a British birth cohort study. BMJ

468

470 Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C. Age, Sex, and Smoking Are 471 Predictors of Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor–Binding 472 Protein 3. J Clin Oncol. 1999;17(3):813-813. doi:10.1200/JCO.1999.17.3.813 473 Chigogora S, Zaninotto P, Kivimaki M, Steptoe A, Batty GD. Insulin-like growth factor 1 and risk 474 of depression in older people: the English Longitudinal Study of Ageing. Transl Psychiatry. 475 2016;6(9):e898-e898. doi:10.1038/tp.2016.167 476 Hardy R, Maddock J, Ghosh AK, Hughes AD, Kuh D. The relationship between pubertal timing 477 and markers of vascular and cardiac structure and function in men and women aged 60-64 478 years. Sci Rep. 2019;9. doi:10.1038/s41598-019-47164-x 479 Goldberg DP, Hillier VF. A scaled version of the General Health Questionnaire. *Psychol Med*. 480 1979;9(1):139-145. doi:10.1017/s0033291700021644 481 31. James S-N, Davis D, O'Hare C, et al. Lifetime affective problems and later-life cognitive state: 482 Over 50 years of follow-up in a British birth cohort study. J Affect Disord. 2018;241:348-355. 483 doi:10.1016/j.jad.2018.07.078 484 Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in 485 R. J Stat Softw. 2011;45(1):1-67. doi:10.18637/jss.v045.i03 486 R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for 487 Statistical Computing; 2018. https://www.R-project.org/ 488 Davis D, Bendayan R, Muniz Terrera G, Hardy R, Richards M, Kuh D. Decline in Search Speed 489 and Verbal Memory Over 26 Years of Midlife in a British Birth Cohort. Neuroepidemiology. 490 2017;49(3-4):121-128. doi:10.1159/000481136 491 35. Okereke O, Kang JH, Ma J, Hankinson SE, Pollak MN, Grodstein F. Plasma IGF-I levels and 492 cognitive performance in older women. Neurobiol Aging. 2007;28(1):135-142. 493 doi:10.1016/j.neurobiolaging.2005.10.012 494 Perice L, Barzilai N, Verghese J, et al. Lower circulating insulin-like growth factor-l is associated 495 with better cognition in females with exceptional longevity without compromise to muscle 496 mass and function. Aging. 2016;8(10):2414-2424. doi:10.18632/aging.101063 497 37. Tumati S, Burger H, Martens S, van der Schouw YT, Aleman A. Association between Cognition 498 and Serum Insulin-Like Growth Factor-1 in Middle-Aged & Older Men: An 8 Year Follow-Up 499 Study. PloS One. 2016;11(4):e0154450. doi:10.1371/journal.pone.0154450 500 Piriz J, Muller A, Trejo JL, Torres-Aleman I. IGF-I and the aging mammalian brain. Exp Gerontol. 501 2011;46(2-3):96-99. doi:10.1016/j.exger.2010.08.022 502 Serhan A, Aerts JL, Boddeke EWGM, Kooijman R. Neuroprotection by Insulin-like Growth 503 Factor-1 in Rats with Ischemic Stroke is Associated with Microglial Changes and a Reduction in 504 Neuroinflammation. Neuroscience. 2020;426:101-114. doi:10.1016/j.neuroscience.2019.11.035

Deng W, Aimone JB, Gage FH. New neurons and new memories: how does adult hippocampal

neurogenesis affect learning and memory? Nat Rev Neurosci. 2010;11(5):339-350.

doi:10.1038/nrn2822

505

506

508 Fernandez AM, Torres-Alemán I. The many faces of insulin-like peptide signalling in the brain. 509 Nat Rev Neurosci. 2012;13(4):225-239. doi:10.1038/nrn3209 510 42. Westwood AJ, Beiser A, DeCarli C, et al. Insulin-like growth factor-1 and risk of Alzheimer 511 dementia and brain atrophy. Neurology. 2014;82(18):1613-1619. 512 doi:10.1212/WNL.0000000000000382 513 Saber H, Himali JJ, Beiser AS, et al. Serum Insulin-Like Growth Factor 1 and the risk of Ischemic 514 Stroke: The Framingham Study. *Stroke*. 2017;48(7):1760-1765. 515 doi:10.1161/STROKEAHA.116.016563 516 Åberg D, Jood K, Blomstrand C, et al. Serum IGF-I Levels Correlate to Improvement of 517 Functional Outcome after Ischemic Stroke. J Clin Endocrinol Metab. 2011;96(7):E1055-E1064. 518 doi:10.1210/jc.2010-2802 519 45. Tarantini S, Valcarcel-Ares NM, Yabluchanskiy A, et al. Insulin-like growth factor 1 deficiency 520 exacerbates hypertension-induced cerebral microhemorrhages in mice, mimicking the aging 521 phenotype. *Aging Cell*. 2017;16(3):469-479. doi:10.1111/acel.12583 522 Allard JB, Duan C. IGF-Binding Proteins: Why Do They Exist and Why Are There So Many? Front 523 Endocrinol. 2018;9. doi:10.3389/fendo.2018.00117 524 Baxter RC. Insulin-like growth factor binding protein-3 (IGFBP-3): Novel ligands mediate 525 unexpected functions. J Cell Commun Signal. 2013;7(3):179-189. doi:10.1007/s12079-013-526 0203-9 527 Wennberg AMV, Hagen CE, Machulda MM, et al. The association between peripheral total IGF-528 1, IGFBP-3, and IGF-1/IGFBP-3 and functional and cognitive outcomes in the Mayo Clinic Study 529 of Aging, Neurobiol Aging, 2018;66:68-74, doi:10.1016/j.neurobiolaging,2017.11.017 530 Almeida OP, Hankey GJ, Yeap BB, Paul Chubb SA, Gollege J, Flicker L. Risk of prevalent and 531 incident dementia associated with insulin-like growth factor and insulin-like growth factor-532 binding protein 3. Mol Psychiatry. 2018;23(8):1825-1829. doi:10.1038/mp.2017.152 533 Dai H, Goto Y, Itoh M. Insulin-Like Growth Factor Binding Protein-3 Deficiency Leads to 534 Behavior Impairment with Monoaminergic and Synaptic Dysfunction. Am J Pathol. 535 2017;187(2):390-400. doi:10.1016/j.ajpath.2016.10.011 536 Johnsen SP, Hundborg HH, Sørensen HT, et al. Insulin-Like Growth Factor (IGF) I, -II, and IGF 537 Binding Protein-3 and Risk of Ischemic Stroke. J Clin Endocrinol Metab. 2005;90(11):5937-5941. 538 doi:10.1210/jc.2004-2088 539 Armbrust M, Worthmann H, Dengler R, et al. Circulating Insulin-like Growth Factor-1 and 540 Insulin-like Growth Factor Binding Protein-3 predict Three-months Outcome after Ischemic 541 Stroke. Exp Clin Endocrinol Diabetes Off J Ger Soc Endocrinol Ger Diabetes Assoc. 542 2017;125(7):485-491. doi:10.1055/s-0043-103965 543 Chang K-H, Chan-Ling T, McFarland EL, et al. IGF binding protein-3 regulates hematopoietic 544 stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad 545 Sci. 2007;104(25):10595-10600. doi:10.1073/pnas.0702072104 546 Reik W, Constancia M, Dean W, et al. Igf2 imprinting in development and disease. Int J Dev 547

Biol. 2000;44(1):145-150.

548 Min DY, Jung E, Kim J, Lee YH, Shin SY. Leptin stimulates IGF-1 transcription by activating AP-1 549 in human breast cancer cells. BMB Rep. 2019;52(6):385-390. 550 Kalmijn S, Janssen J a. MJL, Pols H a. P, Lamberts SWJ, Breteler MMB. A Prospective Study on 551 Circulating Insulin-Like Growth Factor I (IGF-I), IGF-Binding Proteins, and Cognitive Function in 552 the Elderly. J Clin Endocrinol Metab. 2000;85(12):4551-4555. doi:10.1210/jcem.85.12.7033 553 Ito Y, Nakachi K, Imai K, et al. Stability of Frozen Serum Levels of Insulin-like Growth Factor-I, 554 Insulin-like Growth Factor-II, Insulin-like Growth Factor Binding Protein-3, Transforming 555 Growth Factorβ, Soluble Fas, and Superoxide Dismutase Activity for the JACC Study. J 556 Epidemiol. 2005;15(Supplement_I):S67-S73. doi:10.2188/jea.15.S67 557 Bereket A, Wilson TA, Blethen SL, et al. Effect of short-term fasting on free/dissociable insulinlike growth factor I concentrations in normal human serum. J Clin Endocrinol Metab. 558 559 1996;81(12):4379-4384. doi:10.1210/jcem.81.12.8954045 560 Yamamoto H, Sohmiya M, Oka N, Kato Y. Effects of aging and sex on plasma insulin-like growth 561 factor I (IGF-I) levels in normal adults. Acta Endocrinol (Copenh). 1991;124(5):497-500. 562 doi:10.1530/acta.0.1240497 563 60. Joseph D'Ercole A, Ye P. Expanding the Mind: Insulin-Like Growth Factor I and Brain 564 Development. Endocrinology. 2008;149(12):5958-5962. doi:10.1210/en.2008-0920 Al-Delaimy WK, von Muhlen D, Barrett-Connor E. IGF-1 and IGFBP-1 and Cognitive Function in 565 566 Older Men and Women. J Am Geriatr Soc. 2009;57(8):1441-1446. doi:10.1111/j.1532-5415.2009.02343.x 567 568 569 570 571 572 573

574 Table 1

| | NSHD (n=1762) Ir | | | Insight 46 (n=378) | |
|--|-------------------|-------------------|------------------|------------------------------|----------------------|
| | 53 Years | 60-64 Years | 69 Years | 69 – 71 years | P-value ¹ |
| Exposures | | | | | |
| GF- levels (nmol/L) | 26.22 (9.00) | 23.00 (7.71) | | | < 0.001 |
| IGFBP-3 levels (nmol/L) | 173.22 (39.31) | 120.11 (30.16) | | | < 0.001 |
| GF- / GFBP-3 molar ratio | 0.16 (0.06) | 0.20 (0.06) | | | < 0.001 |
| GF- evels (nmol/L) | 99.82 (32.36) | 87.86 (38.60) | | | < 0.001 |
| Cognitive tests | | | | | |
| Addenbrooke's Cognitive Examination | | | 91.52 | | |
| (ACE-III) score Visual Letter Search (VLS) score | 283.52 | 268.25 | (6.01) 263.56 | | < 0.001 |
| Word Learning Test (WLT) score | (73.34) 24.87 | (70.54) 24.68 | (74.32) 22.38 | | < 0.00 |
| | (6.12) | (6.06) | (6.13) | | |
| Insight 46 MRI measures | | | | | |
| Age at scan | | | | 70.67 | |
| Hippocampal volume (ml) | | | | (0.67) 3.13 (0.33) | |
| Total intracranial volume (ml) | | | | 1432.86 | |
| White matter hyperintensity volume ² (ml) | | | | (127.58) 3.08 | |
| Whole brain volume (ml) | | | | (5.19) 1101.38 (95.34) | |
| Model covariates | | | | | |
| Early life cognition | 0.14 (0.69) | | | | |
| Affective Symptoms Case Status | | | | | |
| Non-case | 1313 (81%) | 1247 (83%) | 1505 (86%) | | |
| Case | 316 (19%) | 264 (17%) | 251 (14%) | | |
| Educational attainment | (1570) | (1770) | (1470) | | |
| No qualifications/vocational only | 637 (36%) | | | | |
| O-Level/A-Level or equivalent | 835 (48%) | | | | |
| Higher | 272 (16%) | | | | |
| Smoking status | (20/0) | | | | |
| Current smoker | 315 | 148 | 525 | | |
| | (19%) | (10%) | (9%) | | |
| Ex smoker | 842 | 875 | 1061 | | |
| Mayorarala | (51%) 507 | (58%) 489 | (61%) 525 | | |
| Never smoker | (30%) | (32%) | (30%) | | |

¹P-values were calculated using a one-way ANOVA for continuous variables. ²Median and interquartile range

575

576

presented for non-normally distributed variables

Figures

Figure 1

581

578

579




Figure 2

Age at cognitive testing




Figure 3





Figure 4



598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

Legends for Figures and Tables Table 1: Table presents variable information for the sample (n = 1762 (NSHD) and n= 378 (INSIGHT)) prior to imputation. Figure 1: NSHD study flow diagram. Abbreviations: Insulin-Growth Factor-I (IGF-I), Insulin Growth Factor-II (IGF-II), Insulin-Growth Factor Binding Protein-3 (IGFBP-3), Addenbrookes Cognitive Exam-III (ACE-III), Word Learning Test (WLT), VLS (Visual Letter Search) test, Whole Brain Volume (WBV), White Matter Hyperintensity volume (WMHV), Mean Hippocampal Volume (MHV). Figure 2: Beta coefficient and 95% confidence interval for the effect of IGF-I, IGFBP-3 and IGF-I/IGFBP-3 at ages 53y and 60-64y on visual memory (WLT) and processing speed (VLS) at ages 60-64y and 69y and cognitive state (ACE-III) at age 69y. Models were adjusted for sex (base model), sex, early life cognition and lifetime education (+ childhood cognition and education model), sex, early life cognition, lifetime education and smoking (+ lifestyle factors) and sex, early life cognition, lifetime education, smoking and depressive symptoms (+depressive symptoms). Abbreviations: Insulin-Growth Factor-I (IGF-I), Insulin-Growth Factor Binding Protein-3 (IGFBP-3), Addenbrookes Cognitive Exam-III (ACE-III), Word Learning Test (WLT), VLS (Visual Letter Search) test. * significant at p < .05, ** significant at p < .01.

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635


636

637


638

Figure 3: Beta coefficient and 95% confidence interval for the effect of IGF-I, IGFBP-3 and IGF-I/IGFBP-3 at ages 53y and 60-64y on Total Brain Volume (TBV), White Matter Hyperintensity volume (WMHV) and Mean Hippocampal Volume (MHV) at age 69y in the Insight 46 sub-study. Models were adjusted for sex and age at scan (base model), sex, early life cognition and lifetime education (+ childhood cognition and education model), sex, age at scan, early life cognition, lifetime education and smoking (+ lifestyle factors) and sex, age at scan, early life cognition, lifetime education, smoking and depressive symptoms (+depressive symptoms). ¹Effect sizes are shown on a logarithmic scale.* significant at p < .05, ** significant at p < .01. Figure 4: Predicted scores and 95% confidence intervals for the effect of IGF-II tertiles at ages 53y and 60-64y on ACE-III, WLT and VLS predicted score, in sex-adjusted and fully adjusted models (sex, early life cognition, lifetime education, smoking and depressive symptoms). Tertile 2 presents the reference category used in the regression. Abbreviations: Insulin-Growth Factor-I (IGF-I), Insulin-Growth Factor Binding Protein-3 (IGFBP-3), Addenbrooke's Cognitive Exam-III (ACE-III), Word Learning Test (WLT), VLS (Visual Letter Search) test. * significant at p < .05, ** significant at p < .01.





Age at cognitive testing



Base

model

cognition and education

Model

+Lifestyle

factors

+Depressive

symptoms

Age at cognitive testing

